Cancer, Hypoxia, and Metabolism

SEP 11, 2026 · JOURNAL ARTICLE

Lipid metabolism reprogramming: key mechanism of breast cancer endocrine therapy resistance

Frontiers in Oncology

This is a narrative review synthesizing mechanistic hypotheses about lipid metabolism in endocrine resistance; it raises questions and proposes connections rather than presenting original empirical evidence or clinical outcomes.

SEP 10, 2026 · JOURNAL ARTICLE

ECT2 antagonizes lipoic acid to modulate papillary thyroid carcinoma progression through energy metabolism pathways

Cancer Cell International

Mechanistic in vitro study in cell lines with RNA sequencing showing ECT2's role in PTC proliferation and drug resistance; lacks in vivo validation, clinical trial data, or prospective patient outcomes.

SEP 10, 2026 · JOURNAL ARTICLE

ROS-autocatalytic nanoplatform interfering astrocyte-cancer crosstalk and enhancing glioblastoma therapy

Nature Communications

Preclinical proof-of-concept study demonstrating a novel nanoplatform mechanism in cell and animal models, without human efficacy data or direct comparison to standard therapy.

SEP 10, 2026 · REVIEW

Role of hypoxia-inducible factor – 1 alpha on the progression of cervical intraepithelial neoplasia and cervical cancer: a narrative review

Frontiers in Oncology

A narrative review synthesizing mechanistic evidence and experimental findings on HIF-1α in cervical cancer progression, raising questions about therapeutic targets rather than reporting clinical trial outcomes or definitive clinical evidence.

SEP 10, 2026 · JOURNAL ARTICLE

Shikonin as a Parkin-dependent hypoxia-selective agent against triple-negative breast cancer identified by machine learning

BMC Cancer

In vitro mechanistic study using cell lines and machine learning on retrospective data; no clinical trial, no animal efficacy model, and no direct evidence of human benefit. Raises questions about shikonin's potential but does not answer them.

SEP 9, 2026 · JOURNAL ARTICLE

Association of PET/CT-Derived Metabolic Parameters with Pathological Complete Response After Neoadjuvant Systemic Therapy in Breast Cancer: An Analysis Across Molecular Subtypes

Diagnostics

Retrospective single-center study of moderate size showing PET/CT parameters independently predict pathological complete response with improved model discrimination, but lacks prospective validation and external generalization.

SEP 9, 2026 · JOURNAL ARTICLE

A Biomimetic cascade nanoreactor enabled by tumor microenvironment remodeling for precise CO release and enhanced cu-mediated chemodynamic therapy

Journal of Nanobiotechnology

Preclinical study demonstrating a novel nanomaterial design with in vitro and in vivo efficacy in cancer models, but lacking clinical translation, mechanistic validation in human tissue, or comparison to standard therapies.

SEP 9, 2026 · JOURNAL ARTICLE

UQCRC2 lactylation-mediated mitophagy orchestrates colorectal cancer cell metabolism to establish a drug-tolerant state during chemotherapy

Molecular Cancer

Mechanistic study in cell and animal models identifying a pathway linking lactylation to drug tolerance, with clinical associations but no prospective clinical trial or intervention outcome data.